A randomized phase II trial of fludarabine/melphalan 140 vs fludarabine/melphalan 100 followed by allogeneic peripheral blood stem cell or bone marrow transplantation for patients with multiple myeloma.

Trial Profile

A randomized phase II trial of fludarabine/melphalan 140 vs fludarabine/melphalan 100 followed by allogeneic peripheral blood stem cell or bone marrow transplantation for patients with multiple myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Fludarabine (Primary) ; Melphalan (Primary) ; Rituximab
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Mar 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
    • 11 Jan 2012 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top